Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ReaVen-P is a phytopharmaceutical gel developed by the Institute for Medicinal Plant Research "Dr Josif Pančić" in Serbia. It is a combination product formulated with liquid extracts of horse chestnut (*Aesculus hippocastanum*), ginkgo (*Ginkgo biloba*), and sweet clover (*Melilotus officinalis*). The gel is primarily indicated for the relief of symptoms associated with chronic venous insufficiency, such as heavy legs, swelling, pain, and cramps in the calves. Its mechanism of action involves the venotonic and anti-edematous effects of escin (from horse chestnut), which reduces capillary permeability by inhibiting enzymes like hyaluronidase. Additionally, ginkgo extracts improve local microcirculation, and sweet clover enhances lymphatic drainage through the action of coumarins.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ReaVen-P.